Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors.

Journal of immunotherapy (Hagerstown, Md. : 1997) - 1 Mar 1999

Khleif S N, Abrams S I, Hamilton J M, Bergmann-Leitner E, Chen A, Bastian A, Bernstein S, Chung Y, Allegra C J, Schlom J

Abstract excerpt

Mutations in the ras genes occur in 20% of all human cancers. These genes, in turn, produce mutated proteins that are unique to cancer cells, rendering them distinguishable from normal cells by the immune system. Thus, mutated Ras proteins may form potential targets for immune therapy. We conducted a phase I/pilot clinical trial in patients with advanced cancers to test the toxicity and the ability to induce an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to CD4-Positive T-Lymphocytes

Share to CD8-Positive T-Lymphocytes

Share to Lymphocyte Activation

Share to Neoplasms

Share to ras Proteins

Share to Vaccination

Source

Identifiers

PMID: 10093040
DOI: 10.1097/00002371-199903000-00007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors.PMID 10093040Read ↗

An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.Semantic proximity Read ↗

HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.Semantic proximity Read ↗

Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers.Semantic proximity Read ↗

Subunit peptide cancer vaccines targeting activating mutations of the p21 ras proto-oncogene.Semantic proximity Read ↗

Induction in transgenic mice of HLA-A2.1-restricted cytotoxic T cells specific for a peptide sequence from a mutated p21ras protein.Semantic proximity Read ↗

Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation.Semantic proximity Read ↗

Cancer vaccines: moving beyond current paradigms.Semantic proximity Read ↗

Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation.Semantic proximity Read ↗

T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes.Semantic proximity Read ↗

Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes.Semantic proximity Read ↗

p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly-->Asp).Semantic proximity Read ↗

Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.